$0.90
28.48% yesterday
Nasdaq, Nov 15, 06:37 pm CET
ISIN
US2697961082
Symbol
EGRX
Sector
Industry

Eagle Pharmaceuticals, Inc. Stock price

$0.65
+0.05 8.38% 1M
-3.96 85.89% 6M
-4.58 87.57% YTD
-8.18 92.64% 1Y
-50.33 98.72% 3Y
-56.55 98.86% 5Y
-11.85 94.80% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.05 7.17%
ISIN
US2697961082
Symbol
EGRX
Sector
Industry

Key metrics

Market capitalization $8.45m
Enterprise Value $65.55m
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.25
P/S ratio (TTM) P/S ratio 0.03
Revenue growth (TTM) Revenue growth -5.38%
Revenue (TTM) Revenue $257.55m
EBIT (operating result TTM) EBIT $42.46m
Free Cash Flow (TTM) Free Cash Flow $-9.39m
Cash position $15.35m
EPS (TTM) EPS $0.91
Short interest 4.19%
Show more

Is Eagle Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Eagle Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:

1x Buy
50%
1x Sell
50%

Analyst Opinions

2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:

Buy
50%
Sell
50%

Financial data from Eagle Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '23
+/-
%
258 258
5% 5%
100%
- Direct Costs 78 78
8% 8%
30%
180 180
10% 10%
70%
- Selling and Administrative Expenses 80 80
1% 1%
31%
- Research and Development Expense 36 36
19% 19%
14%
64 64
14% 14%
25%
- Depreciation and Amortization 22 22
284% 284%
9%
EBIT (Operating Income) EBIT 42 42
39% 39%
16%
Net Profit 12 12
48% 48%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Eagle Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eagle Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 4 hours ago
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has notified The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the “SEC”) to complete the previously-disclosed process t...
Neutral
Accesswire
24 days ago
WILMINGTON, DE / ACCESSWIRE / October 22, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ GM:EGRX) on behalf of stockholders.
Positive
GuruFocus
about one month ago
On October 3, 2024, Union Square Park Capital Management, LLC (Trades, Portfolio) made a significant move in the pharmaceutical sector by acquiring 1,191,490 shares of Eagle Pharmaceuticals Inc (EGRX, Financial). This transaction marked a new holding for the firm, purchased at a price of $1.99 per share.
More Eagle Pharmaceuticals, Inc. News

Company Profile

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Head office United States
CEO Michael Graves
Founded 2007
Website www.eagleus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today